Improvement of plateletpheresis via technical modification on the MCS+. Issue 3 (15th June 2015)

• Record Type: Journal Article
• Authors: Zhou, Q.; Yu, X.; Liu, L.; Cai, Y.
• Is Part Of: Transfusion medicine. Volume 25:Issue 3(2015)
• Page Start: 184
• Page End: 188
• Publication Date: 2015-06-15
• Subjects: Blood -- Transfusion -- Periodicals; 615.39
• DOI: 10.1111/tme.12208
• Languages: English
• ISSNs: 0958-7578

Abstract

<abstract abstract-type="main" id="tme12208-abs-0001"> <title>SUMMARY</title> <sec id="tme12208-sec-0001" sec-type="section"> <title>Background</title> <p id="tme12208-para-0001">With the advantage of easy operation and high reliability, Haemonetics multicomponent collection system (MCS+) is widely used as a blood cell separator in clinical application.</p> </sec> <sec id="tme12208-sec-0002" sec-type="section"> <title>Objectives</title> <p id="tme12208-para-0002">The aim of this study was to evaluate the effect of technical parameter modification as utilised on the MCS+ to improve the quality of platelet yielded as well as donor comfort.</p> </sec> <sec id="tme12208-sec-0003" sec-type="section"> <title>Methods</title> <p id="tme12208-para-0003">After informed consent, a total of 118 donors, well matched for baseline parameters, were included in the study from December 2012 to April 2013. Sixty‐one donors underwent single‐dose plateletpheresis (SDP), and the other 57 donors underwent double‐dose plateletpheresis (DDP) before and after technical modification on the MCS+, respectively, according to the manufacturer's instructions. The procedures were evaluated, focusing on whole blood processed (WBP), processing time (PT) and number of cycles were measured, as well as the quality of products.</p> </sec> <sec id="tme12208-sec-0004" sec-type="section"> <title>Results</title> <p id="tme12208-para-0004">No severe adverse reaction was found during donation. WBP, PT and number of cycles after modification were all reduced significantly in both SDP and DDP groups (<italic>P</italic> < 0·01). In addition, 80·51 % (95 in 118) of the total post‐modification products were qualified, presenting with high quality. Besides, the comfort of donors was also improved probably because of the reduced PT.</p> </sec> <sec id="tme12208-sec-0005" sec-type="section"> <title>Conclusion</title> <p id="tme12208-para-0005">Adjustment of the relevant technical parameters on MCS+ could produce a beneficial effect on the procedure measures and ensure a high‐quality platelet production.</p> </sec> </abstract>